NOVACYT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.724 EUR | -1.09% |
|
-9.16% | +1.54% |
| May. 01 | Novacyt Says UK Court Dismissed Government's Summary Judgment Application | MT |
| May. 01 | Novacyt notes court dismissal of UK DHSC summary judgment application | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 95.78M 104M | Sales 2022 | 21.04M 22.84M | Capitalization | 76.79M 83.36M |
|---|---|---|---|---|---|
| Net income 2021 | -9M -9.77M | Net income 2022 | -25M -27.14M | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 99.9M 108M | Net cash position 2022 | 86.29M 93.68M | EV / Sales 2022 | -0.45 x |
| P/E ratio 2021 |
-26.3
x | P/E ratio 2022 |
-2.99
x | Employees | 120 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novacyt
More news
| 1 day | -1.09% | ||
| 1 week | -9.16% | ||
| Current month | -12.88% | ||
| 1 month | +14.92% | ||
| 3 months | +28.94% | ||
| 6 months | +20.07% | ||
| Current year | +1.54% |
1 week
0.71
0.79
1 month
0.710.88
Current year
0.490.88
1 year
0.421.00
3 years
0.425.89
5 years
0.0613.96
10 years
0.0613.96
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Gibson
DFI | Director of Finance/CFO | 41 | 17-03-31 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 16-04-30 |
James McCarthy
BRD | Director/Board Member | 58 | 21-01-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Brown
BRD | Director/Board Member | 69 | 23-09-07 |
Lyn Rees
CEO | Chief Executive Officer | 51 | 23-09-07 |
| Chairman | 58 | 14-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 0.724 | -1.09% | 123,527 |
| 24-05-15 | 0.732 | -2.27% | 126,577 |
| 24-05-14 | 0.749 | 0.00% | 94,138 |
| 24-05-13 | 0.749 | -4.95% | 213,559 |
| 24-05-10 | 0.788 | -1.13% | 87,302 |
Real-time Euronext Paris, May 16, 2024 at 11:35 am EDT
More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.54% | 55.54M | |
| -10.03% | 1.16B | |
| -20.09% | 131M | |
| +0.16% | 73.3M | |
| +3.39% | 59.57M | |
| -2.99% | 51.18M |
- Stock Market
- Equities
- ALNOV Stock
